Mah S C, Opperman J R, Baum H P, Hofbauer K G
Cardiovascular Research Department, Ciba-Geigy Limited, Basel, Switzerland.
J Pharmacol Exp Ther. 1988 Jun;245(3):1021-7.
The renal tubular arginine vasopressin receptor antagonist, d-(CH2)5-D-Tyr(Et)VAVP, is a potent inhibitor of the vasopressin-induced stimulation of adenylate cyclase in rat renal medullary homogenates in vitro. In acute experiments in vivo, this antagonist increased urine volume and decreased urine osmolality after i.v. or s.c. administration in normally hydrated or dehydrated Sprague-Dawley rats. It did not show any effects in water-loaded rats. The duration of action of the antagonist was between 3 to 4 hr. Chronic i.v. infusion or repeated s.c. injections did not result in a persistent diabetes insipidus. A transient rise in water excretion was followed by a progressive normalization. The marked initial water loss was fully compensated for by an increased water intake so that plasma volume and extracellular fluid volume remained unchanged. After 1 week of treatment with the antagonist, glomerular filtration rate and plasma renin activity were not significantly different from base-line values. Only small functional deficits in renal concentrating capacity became manifest when drinking water was withheld. It is possible that the activation of endogenous compensatory mechanisms restored water balance during chronic arginine vasopressin receptor blockade. An intrinsic agonism of this antagonist, which was not detectable in acute experiments, might have contributed to the normalization of water balance by limiting the maximum anti-antidiuretic effects of renal tubular arginine vasopressin receptor blockade.
肾小管精氨酸血管加压素受体拮抗剂d-(CH2)5-D-Tyr(Et)VAVP,在体外是大鼠肾髓质匀浆中血管加压素诱导的腺苷酸环化酶刺激作用的有效抑制剂。在急性体内实验中,给正常水合或脱水的斯普拉-道利大鼠静脉注射或皮下注射该拮抗剂后,尿量增加,尿渗透压降低。在水负荷大鼠中未显示任何作用。拮抗剂的作用持续时间为3至4小时。慢性静脉输注或重复皮下注射不会导致持续性尿崩症。短暂的水排泄增加后会逐渐恢复正常。最初明显的水分流失通过增加水摄入量得到了充分补偿,因此血浆容量和细胞外液容量保持不变。用拮抗剂治疗1周后,肾小球滤过率和血浆肾素活性与基线值无显著差异。仅在禁水时才出现肾浓缩能力的微小功能缺陷。内源性代偿机制的激活可能在慢性精氨酸血管加压素受体阻断期间恢复了水平衡。这种拮抗剂的内在激动作用在急性实验中未被检测到,可能通过限制肾小管精氨酸血管加压素受体阻断的最大抗利尿作用,有助于水平衡的恢复正常。